Delivery of formoterol from a novel multi-dose inhaler Airmax™

Respiratory Medicine

Volumn 96, Issue 6, 2002, Pages 397-403

  Zeng, Xian Ming ^a   Jones, S ^a   O'Leary, D ^a   Phelan, M ^b   Colledge, J ^c  

^a IVAX Pharmaceutical UK Ltd   (United Kingdom)

^b IVAX Pharmaceuticals   (Ireland)

^c ASTELLAS PHARMA INC   (Japan)

Author keywords

Active metering; Airmax ; Cyclone separator; Dry powder inhalers; Formoterol

Indexed keywords

FORMOTEROL; FORMOTEROL FUMARATE; LACTOSE; BRONCHODILATING AGENT; ETHANOLAMINE DERIVATIVE;

ACCURACY; AEROSOL; APPARATUS; ARTICLE; BREATHING; CONTROLLED STUDY; CYCLONE SEPARATOR; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EQUIPMENT DESIGN; LIQUID; METERED DOSE INHALER; PARTICLE SIZE; PRIORITY JOURNAL; SAMPLING; STATISTICAL ANALYSIS; TECHNOLOGY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG DISEASE; NEBULIZER; POWDER; STANDARD;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; EQUIPMENT DESIGN; ETHANOLAMINES; HUMANS; LUNG DISEASES; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POWDERS;

EID: 0036591409     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2002.1361     Document Type: Article

References (14)

1. Crowder TM, Louvey MD, Sethuraman VV, Smyth HDC, Hickey AJ. An odyssey in inhaler formulation and design. Pharm Tech 2001; July: 99-113.
2. Snell NJ. The need for new propellants in MDI: problems and solutions. J Pharm Med 1995; 5: 153-160.
3. Hill LS, Slater AL. A comparison of the performance of two modern multidose dry powder asthma inhalers. Respir Med 1998; 92: 105-110.
4. Lipworth BJ, Clark DJ. Comparative lung delivery of salbutamol given via Turbuhaler and Diskus dry powder inhaler devices. Eur J Clin Pharmacol 1997; 53: 47-49.
5. Bisgaard H, Klug B, Sumby BS, et al. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur Respir J 1998; 11: 1111-1115.
6. Bisgaard H, Klug PKP, Burnell P, Sumby BS. Use of inhalation profiles from paediatric asthmatics using the Diskus and Turbuhaler inhalers to evaluate product performance in vitro. Am J Respir Crit Care Med 1996; 153: A75.
7. Sharma PK, Edwards K, Halle C, et al. Perception among pediatric patients of the Diskus inhaler, a novel multidose powder inhaler for use in the treatment of asthma: comparison with the Turbuhaler. Clin Drug Invest 1996; 11: 145-153.
8. van der Palen J, Klein JJ, Schildkamp AM. Comparison of the new multidose powder inhaler (Diskus/ Accuhaler) and the Turbuhaler regarding preference and ease of use. J Asthma 1998; 35: 147-152.
9. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers: implications for in vitro testing. J Aerosol Med 1993; 6: 99-110.
10. Faulds D, Hjollingshead LM, Goa KL. Formoterol: a review of its pharmacological properties and therapeutic potential in reversibly obstructive airways disease. Drugs 1991; 42: 115-137.
11. Gonda I. Aerosols for delivery of therapeutic agents to the respiratory tract. Crit Rev Ther Drug 1990; 6: 273-313.
12. Hickey AJ, Concessio NM, Van MM, Platz AM. Factors influencing the dispersion of dry powders as aerosols. Pharm Tech 1994; 18: 58-82.
13. Zeng XM, Martin GP, Marriott C. Particulate Interactions in Dry Powder Formulations for Inhalation. London: Taylor & Francis, 2001.
14. Ower E, Pankhurst RC. The Measurement of Airflow, 5th edn. Oxford Diagnostic, Oxford: Pergamon Press, 1977.